Who Owns Cosentyx?
Cosentyx is owned by Novartis, a publicly traded Swiss multinational pharmaceutical company. As Novartis's flagship immunology biologic drug, Cosentyx generated strong sales growth of 25% in 2024 and is projected to reach $9.51 billion in global market value by 2030. Novartis is headquartered in Basel, Switzerland and trades on SIX (NOVN) and NASDAQ (NVS).
Parent Company
Novartis
Founded
2015
Status
Publicly Traded
Headquarters
Basel, Switzerland
Who Owns Cosentyx?
- Parent Company: Novartis
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: SIX: NOVN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Cosentyx | Novartis | Wholly owned |
History of Cosentyx
- Founded: 2015
- Founders: Novartis (internal development)
Cosentyx was developed by Novartis through extensive research and clinical trials focused on treating autoimmune diseases. The drug was approved by the FDA in 2015 as a treatment for moderate to severe plaque psoriasis. Cosentyx represented a significant breakthrough in immunology as the first IL-17A inhibitor to market, offering patients a novel mechanism of action for treating inflammatory conditions.
The development of Cosentyx involved years of research into IL-17 pathway inhibition, a pioneering approach to treating autoimmune diseases. Novartis conducted extensive clinical trials demonstrating the drug's efficacy and safety profile. Cosentyx quickly became one of the most prescribed biologic treatments for psoriasis and related conditions, establishing Novartis as a leader in the immunology space.
Following its initial approval for psoriasis, Cosentyx received approval for additional indications including psoriatic arthritis (2016), ankylosing spondylitis (2016), non-radiographic axial spondyloarthritis (2020), enthesitis-related arthritis and juvenile psoriatic arthritis in pediatric patients (2021). In a significant expansion, the FDA approved Cosentyx in 2023 as the first new biologic treatment option for hidradenitis suppurativa in nearly a decade. This expanded label has allowed Cosentyx to serve a much broader patient population with various autoimmune conditions.
In October 2025, Novartis announced that Cosentyx met all primary and secondary endpoints in the Phase III REPLENISH trial for polymyalgia rheumatica (PMR), demonstrating statistically significant and clinically meaningful sustained remission compared to placebo at Week 52. This breakthrough has positioned Cosentyx for potential approval in yet another inflammatory condition, with submissions to health authorities planned for the first half of 2026.
Over its decade-plus history, Cosentyx has established a robust safety profile with over 10 years of real-world data, having been used to treat more than 1.8 million patients worldwide since its launch. The drug has been approved in over 100 countries and continues to expand its clinical use and market presence as a leading biologic treatment across multiple immunological conditions.
About Novartis
What does Novartis own?
Novartis owns a portfolio of innovative prescription medicines across oncology, immunology, cardiovascular, neuroscience, and ophthalmology. Key products include Cosentyx (inflammatory diseases), Entresto (heart failure), Kisqali (breast cancer), Kesimpta (multiple sclerosis), Leqvio (cholesterol), Zolgensma (gene therapy for spinal muscular atrophy), and Kymriah (CAR-T cell therapy). Novartis spun off its Sandoz generics division in 2023 and its Alcon eye care division in 2019.
Is Novartis publicly traded?
Yes, Novartis AG is listed on the SIX Swiss Exchange under ticker NOVN and on NASDAQ under ticker NVS (as American Depositary Receipts). The company has a broad institutional and retail shareholder base with no single controlling shareholder. Major institutional shareholders include Vanguard Group and BlackRock.
Who founded Novartis?
Novartis was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two of Switzerland's oldest pharmaceutical companies. Ciba-Geigy itself was formed through the 1970 merger of Ciba and Geigy, both founded in Basel in the 19th century. Sandoz was founded in 1886 in Basel. The 1996 merger was one of the largest corporate mergers in history at the time, valued at approximately $63 billion.
Where is Novartis headquartered?
Novartis AG is headquartered in Basel, Switzerland. Basel has been the center of the Swiss pharmaceutical industry for more than a century, and Novartis, Roche, and several other major pharmaceutical companies are headquartered in the city. Novartis operates manufacturing and research facilities in Switzerland, the United States, Germany, Spain, Italy, Japan, China, India, Singapore, and Brazil.
How many products does Novartis sell?
Novartis sells dozens of prescription medicines across multiple therapeutic areas. The company's growth portfolio is led by Cosentyx, Entresto, Kisqali, Kesimpta, Leqvio, Zolgensma, and Kymriah. Novartis has a pipeline of more than 150 projects in clinical development across its therapeutic focus areas. The company sells products in more than 140 countries worldwide.
Who owns Novartis?
Novartis AG is publicly traded on the SIX Swiss Exchange and NASDAQ with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. The Novartis Foundation for Employee Participation holds a significant stake. Major institutional shareholders include Vanguard Group and BlackRock. Vas Narasimhan serves as CEO and Joerg Reinhardt chairs the board.
- Founded: 1996
- Headquarters: Basel, Switzerland
- Company Type: Publicly Traded
- Stock: SIX: NOVN
Where Is Cosentyx Made / Based?
- Headquarters: Basel, Switzerland
- Manufacturing / Operations: Switzerland, Germany, United States
Brands Owned by Novartis
- Afinitor - Prescription oncology medication for treating various cancers including renal ce...
- Alcon - Global leader in eye care products and surgical equipment, specializing in conta...
- Exelon - Brand name for rivastigmine, a prescription cholinesterase inhibitor developed b...
- Gilenya - Prescription immunosuppressant medication for treating relapsing-remitting multi...
- Lamisil - Over-the-counter antifungal medication for treating fungal infections including ...
- Lucentis - Prescription biologic medication for treating age-related macular degeneration a...
- Otrivin - Over-the-counter nasal decongestant spray for relieving nasal congestion from co...
- Sandoz - Independent global leader in generic and biosimilar pharmaceuticals, spun off fr...
- Tasigna - Prescription oncology medication for treating chronic myeloid leukemia, owned by...
- Theraflu - Over-the-counter cold and flu relief medication combining multiple active ingred...
- Voltaren - Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owne...
Cosentyx Ownership: Pros & Cons
Advantages
- +Novel mechanism of action targeting IL-17 pathway
- +Effective treatment for moderate to severe psoriasis and related conditions
- +Approved for multiple autoimmune disease indications
- +Backed by extensive clinical research and safety data
- +Strong efficacy demonstrated in clinical trials
- +Supported by Novartis's research capabilities and pharmaceutical expertise
- +Available globally with established distribution networks
Considerations
- -High cost as a biologic medication
- -Requires regular injections or infusions
- -Potential for serious infections due to immune suppression
- -Not suitable for patients with active infections
- -Requires monitoring by healthcare professionals
- -Competition from other biologic immunology treatments
- -Potential for adverse reactions in some patients
Frequently Asked Questions About Cosentyx
Where to Buy
Disclosure: We may earn commission from purchases
Cosentyx on AmazonNovartis Stock Information
Jobs at Novartis
Latest News About Cosentyx
Related Articles About Cosentyx
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.